September 2005
Pharmaceutical Representative;Sep2005, Vol. 35 Issue 9, p13
Suggests that treatment with Indianapolis, Indiana-based Eli Lilly and Co.'s investigational drug ruboxistaurin mesylate delays vision loss in diabetic patients, but does not prevent the progression of diabetic retinopathy. Highlights of the Phase III research published in the journal "Diabetes"; Evidence that treatment with the highest dose of ruboxistaurin did not significantly reduce the progression of diabetic retinopathy but did decrease the risk of moderate visual loss.


Related Articles

  • Eli Lilly debates potential DR treatment.  // Ophthalmology Times;12/1/2006, Vol. 31 Issue 23, p8 

    The article reports on the consideration of Eli Lilly and Co. about further development of ruboxistaurin mesylate following the U.S. Food and Drugs Administration's (FDA) request for an additional 3-year, phase III clinical trial of the molecule that could treat severe diabetic retinopathy after...

  • Retinopathy Drug in the Works. Trecroci, D. // Diabetes Health;Jul2006, Vol. 15 Issue 7, p33 

    The article reports on the priority review status granted by the U.S. Food and Drug Administration for diabetic retinopathy drug Arxxant from Eli Lilly & Co. It is said that diabetic retinopathy can eventually lead to vision loss and blindness. Eli Lilly states that Arxxant has the chance to...

  • Canadians informed of pioglitazone-related fracture risk.  // Reactions Weekly;5/12/2007, Issue 1151, p2 

    The article reports on the issuance of a health care professional letter and a public communication by pharmaceutical firm Eli Lilly advising of an increased incidence of fractures in women receiving long-term treatment with pioglitazone (Actos) for type 2 diabetes mellitus. The letter and the...

  • American Heart Association.  // BioWorld Today;11/17/2009, Vol. 20 Issue 222, p10 

    This article deals with the results obtained by Eli Lilly and Co. from a study of patients with type II diabetes mellitus and coronary artery disease who received prasugrel and clopidogrel. Particular focus is given to their dosing regimen. According to the study, prasugrel therapy led to a...

  • New data for once-daily linagliptin show durable efficacy over 2 years.  // Biomedical Market Newsletter;9/26/2011, Vol. 21, p815 

    The article reports on the results of a 102-week Phase III clinical study for linagliptin, which showed meaningful and durable reductions in blood glucose for adults with type 2 diabetes (T2D). The aim of the two-year study conducted by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and...

  • Zyprexa and Other Antipsychotic Drugs For Elderly People with Dementia.  // HealthFacts;Jul2007, Vol. 32 Issue 7, p4 

    The article discusses prescription antipsychotic drugs and their effect on demented elderly people. In a study conducted in Ontario and published in a 2007 issue of the "Annals of Internal Medicine," a slight increase in the death rate of those who took the drugs was noted compared to those who...

  • Peginterferon-α-2a.  // Reactions Weekly;Oct2014, Vol. 1522 Issue 1, p134 

    The article presents a case report of a 56-year-old woman who developed retinopathy while receiving peginterferon-alpha-2a.

  • Bevacizumab.  // Reactions Weekly;1/11/2014, Issue 1483, p22 

    The article presents a case study of a 52-year-old woman who experienced conjunctival pyogenic granuloma after she was treated with intravitreal bevacizumab injections for bilateral proliferative diabetic retinopathy and cystoid macular oedima.

  • Improvement Seen in Neuropathy Patients Using Ruboxistaurin.  // Podiatry Management;Nov/Dec2004, Vol. 23 Issue 9, p240 

    Announces the results of the clinical trial conducted by Eli Lilly and Co. on the drug ruboxistaurin as a treatment for diabetic microvascular complications. Improvement in the symptoms of diabetic peripheral neuropathy (DPN) upon administration of the drug; Correlation of diabetic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics